Industry to benefit from EU moves to cut red tape
This article was originally published in SRA
Six measures being taken to simplify the European Union pharmaceutical legislation, including new rules on side effect reporting and changes to marketing authorisations, could significantly reduce the administrative burden on companies and lead to savings of around €155 million, says the European Commission1.
You may also be interested in...
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.
The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage.
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.